Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT PR Newswire - Thu Jan 1, 9:00AM CST

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT).  Such investors are...

GALT : 4.05 (-2.64%)
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm Business Wire - Mon Dec 29, 2025

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or “the Company”)...

GALT : 4.05 (-2.64%)
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 GlobeNewswire - Fri Dec 19, 2025

NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension,...

GALT : 4.05 (-2.64%)
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update GlobeNewswire - Fri Nov 14, 2025

NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...

GALT : 4.05 (-2.64%)
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting GlobeNewswire - Mon Nov 10, 2025

New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kg Using established criteria for clinically meaningful worsening, a lower proportion of...

GALT : 4.05 (-2.64%)
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference GlobeNewswire - Mon Oct 20, 2025

NORCROSS, Ga., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management...

GALT : 4.05 (-2.64%)
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 GlobeNewswire - Tue Oct 7, 2025

NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal...

GALT : 4.05 (-2.64%)
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire - Tue Sep 2, 2025

NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management...

GALT : 4.05 (-2.64%)
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update GlobeNewswire - Thu Aug 14, 2025

NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...

GALT : 4.05 (-2.64%)
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 GlobeNewswire - Wed Jul 9, 2025

GALT : 4.05 (-2.64%)

Barchart Exclusives

CES 2026, Sector Rotation and Other Key Things to Watch this Week Barchart - Sun Jan 4, 12:00PM CST
Markets enter 2026's first full trading week with an extraordinary convergence of events including the Consumer Electronics Show (CES) in Las Vegas where Nvidia CEO Jensen Huang and AMD CEO Lisa Su will deliver keynote speeches that could significantly influence AI infrastructure investment narratives Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot